Page last updated: 2024-11-13

birinapant

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

birinapant: a Smac mimetic with antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID49836020
CHEMBL ID3039522
CHEBI ID177705
SCHEMBL ID10049847
MeSH IDM0586465

Synonyms (51)

Synonym
(2s,2's)-n,n'-[(6,6'-difluoro-1h,1'h-2,2'-biindole-3,3'-diyl)bis{methanediyl[(2r,4s)-4-hydroxypyrrolidine-2,1-diyl][(2s)-1-oxobutane-1,2-diyl]}]bis[2-(methylamino)propanamide]
gt6 ,
CHEBI:177705
birinapant
1260251-31-7
(2s)-n-[(2s)-1-[(2r,4s)-2-[[6-luoro-2-[6-luoro-3-[[(2r,4s)-4-hydroxy-1-[(2s)-2-[[(2s)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1h-indol-2-yl]-1h-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamid
tl-32711
bdbm50071920
birinapant (tl32711)
tl 32711
6o4z07b57r ,
tl32711
unii-6o4z07b57r
birinapant [usan:inn]
D10417
birinapant (usan/inn)
S7015
CHEMBL3039522
gtpl7432
(2s)-n-[(2s)-1-[(2r,4s)-2-[[6-fluoro-2-[6-fluoro-3-[[(2r,4s)-4-hydroxy-1-[(2s)-2-[[(2s)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1h-indol-2-yl]-1h-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanam
CS-1719
HY-16591
smr004702997
MLS006011237
birinapant [usan]
propanamide, n,n'-((6,6'-difluoro(2,2'-bi-1h-indole)-3,3'-diyl)bis(methylene((2r,4s)-4-hydroxy-2,1-pyrrolidinediyl)((1s)-1-ethyl-2-oxo-2,1-ethanediyl)))bis(2-(methylamino)-, (2s,2's)-
birinapant [inn]
birinapant [who-dd]
n,n'-((6,6'-difluoro(1h,1'h-2,2'-biindole)- 3,3'-diyl)bis(methylene((2r,4s)-4-hydroxypyrrolidine-2,1-diyl)((2s)-1- oxobutane-1,2-diyl) bis((2s)-2-(methylamino)propanamide)
propanamide, n,n'-[(6,6'-difluoro[2,2'-bi-1h-indole]-3,3'-diyl)bis[methylene[(2r,4s)-4-hydroxy-2,1-pyrrolidinediyl][(1s)-1-ethyl-2-oxo-2,1-ethanediyl]]]bis[2-(methylamino)-, (2s,2's)-
SCHEMBL10049847
AC-32868
DTXSID30155057
EX-A258
AKOS030526366
(2s,2's)-n,n'-((2s,2's)-((3s,3's,5r,5'r)-5,5'-((6,6'-difluoro-1h,1'h-[2,2'-biindole]-3,3'-diyl)bis(methylene))bis(3-hydroxypyrrolidine-5,1-diyl))bis(1-oxobutane-2,1-diyl))bis(2-(methylamino)propanamide)
mfcd25976869
SW220103-1
DB11782
(2s,2's)-n,n'-[(6,6'-difluoro-1h,1'h-2,2'-biindole-3,3'-diyl)bis{methanediyl[(2r,4s)-4-hydroxypyrrolidine-2,1-diyl][(2s)-1-oxobutane-1,2-diyl]}]bis[2-(methylamino)propanamide] (non-preferred name)
Q27075298
AS-17035
CCG-270498
A852939
birinapant di-hcl
nsc816007
nsc-816007
nsc767128
tl32711 2hcl
tl-32711 2hcl
nsc-767128

Research Excerpts

Overview

Birinapant is a novel SMAC peptidomimetic molecule in clinical development. It was designed to mimic AVPI, the N-terminal tetrapeptide of the second mitochondria-derived activator of caspases.

ExcerptReferenceRelevance
"Birinapant/TL32711 (1) is a bivalent antagonist of the inhibitor of apoptosis (IAP) family of proteins and was designed to mimic AVPI, the N-terminal tetrapeptide of the second mitochondria-derived activator of caspases (Smac/DIABLO). "( Electrophilic Oxidation and [1,2]-Rearrangement of the Biindole Core of Birinapant.
Alexander, MD; Condon, SM; Deng, Y; Haimowitz, T; Hendi, MS; Kumar, PT; LaPorte, MG; Lee, YH; Rippin, SR, 2016
)
2.11
"Birinapant is a novel SMAC peptidomimetic molecule in clinical development. "( SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma Multiforme.
Adelabu, Y; Ahmed, MM; Bernhard, E; Carter, D; Cerna, D; Coleman, CN; Fahim, A; Lim, B; Mitsuuchi, Y; Takebe, N; Teicher, BA; Yoo, S, 2021
)
2.36
"Birinapant (1) is a second-generation bivalent antagonist of IAP proteins that is currently undergoing clinical development for the treatment of cancer. "( Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.
Alexander, MD; Benetatos, CA; Bettjeman, B; Burns, JM; Chunduru, SK; Condon, SM; Cumming, MH; Day, CL; Deng, Y; Feltham, R; Graham, MA; Haimowitz, T; Hendi, MS; Kapoor, GS; Khan, N; Kumar, PT; LaPorte, MG; Lee, YH; Li, X; McKinlay, MA; Mitsuuchi, Y; Neiman, E; Rippin, SR; Seipel, ME; Shi, Y; Silke, J; Vince, JE; Wang, J; Yu, G, 2014
)
3.29

Actions

ExcerptReferenceRelevance
"Birinapant can inhibit the expression of cIAP-1, cIAP-2 and the proteins of Ras-Raf-MEK-ERK signal pathways, so as to activate the mitochondria mediated endogenous apoptosis pathway.Birinapant shows a certain inhibitory effect on liver cancer."( [Anti-hepatoma effects of Smac analogue Birinapant and its related molecular mechanism].
Chen, JY; Jiang, PR; Ke, RJ; Lou, EZ; Xie, JG; Zhu, ML, 2018
)
2.19

Treatment

Pretreatment with birinapant promoted apoptosis and inhibited invasion of liver cancer cells by activating the cIAP1/TRAF3 axis. Treatment with Birinapan alone did not result in a substantial increase in apoptotic cells in this cell line panel.

ExcerptReferenceRelevance
"Pretreatment with birinapant promoted apoptosis and inhibited invasion of liver cancer cells by activating the cIAP1/TRAF3 axis."( SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.
Ding, J; Li, J; Li, Q; Li, Y; Qin, D; Zhang, Y, 2020
)
1.25
"Treatment with Birinapant alone did not result in a substantial increase in apoptotic cells in this cell line panel."( Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant.
Bozkurt, E; Crawford, N; Düssmann, H; Fichtner, M; Halang, L; Kinsella, S; Longley, DB; McAllister, KA; McCann, C; Prehn, JHM; Salvucci, M; Sessler, T, 2020
)
1.13
"Pretreatment with birinapant inhibited the invasion and proliferation of MGC-803 cells and promoted cell apoptosis."( Effects of Birinapant on Proliferation and Invasion of MGC-803 Gastric Cancer Cells and Mechanism Underlying These Effects.
Shuai, LY; Zhu, DL, 2021
)
1.33

Pharmacokinetics

ExcerptReferenceRelevance
" In this study, pharmacokinetic information derived from experiments and the literature was utilized to develop full physiologically-based pharmacokinetic (PBPK) models that characterize individual drugs."( Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.
Jusko, WJ; Straubinger, RM; Trueman, S; Zhu, X, 2018
)
0.7
"To investigate potential mechanisms underlying this synergistic pharmacodynamic interaction, data capturing PANC-1 cell growth, apoptosis kinetics, and cell cycle distribution were integrated with high-quality IonStar-generated proteomic data capturing changes in the relative abundance of more than 3300 proteins as the cells responded to the two drugs, alone and combined."( Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells.
Mager, DE; Niu, J; Qu, J; Straubinger, RM; Wang, X, 2020
)
0.83
" Coupling proteomic and cellular response profiles with multi-scale pharmacodynamic modeling provides a quantitative mechanistic framework for evaluating pharmacodynamically-based drug-drug interactions in combination chemotherapy, and could potentially guide the development of promising drug regimens."( Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells.
Mager, DE; Niu, J; Qu, J; Straubinger, RM; Wang, X, 2020
)
0.83

Compound-Compound Interactions

ExcerptReferenceRelevance
"Antagonists of inhibitors of apoptosis proteins (IAPs), alone or in combination with genotoxic therapeutics, have been shown to efficiently induce cell death in various solid tumors."( Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death.
Alexopoulos, LG; Charles, EM; Hellwig, CT; Rehm, M; Rožanc, J; Vetma, V, 2017
)
0.7
" Second mitochondrial activator of caspase (SMAC) mimetics are the most widely used IAP antagonists currently being tested in clinical trials as a monotherapy and in combination with different chemotherapeutic drugs to target different types of cancer."( Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers.
Dibernardo, G; Memarzadeh, S; Moatamed, NA; Neal, A; Raheseparian, N; Singh, T, 2022
)
1.1

Dosage Studied

ExcerptRelevanceReference
" Studies of TL32711 in xenograft models confirmed a dose-dependent increase in activated caspase-3 6 hours after dosing and provided assay fit-for-purpose confirmation."( Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.
Damour, E; Donohue, J; Doroshow, JH; Esposito, D; Govindharajulu, JP; Hollingshead, MG; Jaganathan, S; Kinders, RJ; Kummar, S; Layhee, A; Mapes, JP; Parchment, RE; Srivastava, AK; Stephen, L; Takebe, N; Tomaszewski, JE, 2016
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency14.74030.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency14.74030.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Baculoviral IAP repeat-containing protein 2Homo sapiens (human)IC50 (µMol)0.05000.00040.31212.7200AID1196848
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein Zika virusEC50 (µMol)0.30000.02200.30730.6000AID1659178
E3 ubiquitin-protein ligase XIAPHomo sapiens (human)Kd0.05000.02800.20510.9000AID1553565
Baculoviral IAP repeat-containing protein 3Homo sapiens (human)Kd0.03600.01290.03060.0430AID1553575
Baculoviral IAP repeat-containing protein 2Homo sapiens (human)Kd0.00100.00100.00950.0170AID1553574
Baculoviral IAP repeat-containing protein 7Homo sapiens (human)Kd0.00100.00100.00750.0140AID1553576
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (84)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
regulation of apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
DNA damage responseE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
Wnt signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of BMP signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of protein ubiquitinationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of type I interferon productionE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of cell population proliferationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
defense response to bacteriumE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
negative regulation of apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of innate immune responseE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of JNK cascadeE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of inflammatory responseE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
neuron apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
copper ion homeostasisE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of apoptosis involved in tissue homeostasisE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleotide-binding oligomerization domain containing 1 signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
protein K63-linked ubiquitinationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
inhibition of cysteine-type endopeptidase activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
positive regulation of protein linear polyubiquitinationE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
regulation of cell cycleE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
apoptotic processBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
cell surface receptor signaling pathwayBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
canonical NF-kappaB signal transductionBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
spermatogenesisBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
positive regulation of protein ubiquitinationBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
regulation of toll-like receptor signaling pathwayBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
non-canonical NF-kappaB signal transductionBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
regulation of RIG-I signaling pathwayBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
regulation of apoptotic processBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
regulation of innate immune responseBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
regulation of inflammatory responseBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
regulation of necroptotic processBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
regulation of cysteine-type endopeptidase activityBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
regulation of cell cycleBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
negative regulation of apoptotic processBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
negative regulation of necroptotic processBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
protein polyubiquitinationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
response to hypoxiaBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
placenta developmentBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
apoptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cell surface receptor signaling pathwayBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
canonical NF-kappaB signal transductionBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of toll-like receptor signaling pathwayBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
non-canonical NF-kappaB signal transductionBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of RIG-I signaling pathwayBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of cell population proliferationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of apoptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
negative regulation of apoptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of innate immune responseBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
response to ethanolBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of cell differentiationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of inflammatory responseBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
response to cAMPBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of cell cycleBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of necroptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
necroptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of non-canonical NF-kappaB signal transductionBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
negative regulation of ripoptosome assembly involved in necroptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of protein K48-linked ubiquitinationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of protein monoubiquitinationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of cysteine-type endopeptidase activityBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of reactive oxygen species metabolic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
positive regulation of protein ubiquitinationBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
negative regulation of necroptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
regulation of apoptotic processBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
lens development in camera-type eyeBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
apoptotic processBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
protein ubiquitinationBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
regulation of cell population proliferationBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
negative regulation of apoptotic processBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
positive regulation of JNK cascadeBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
regulation of natural killer cell apoptotic processBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
positive regulation of protein ubiquitinationBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
regulation of cell cycleBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
ubiquitin-protein transferase activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cysteine-type endopeptidase inhibitor activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
protein bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
identical protein bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
metal ion bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
endopeptidase regulator activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
ubiquitin protein ligase activityE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
protein serine/threonine kinase bindingE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
ubiquitin-protein transferase activityBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
protein bindingBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
transferase activityBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
protein-containing complex bindingBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
metal ion bindingBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
ubiquitin protein ligase activityBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
transcription coactivator activityBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
ubiquitin-protein transferase activityBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
protein bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
zinc ion bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
transferase activityBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
identical protein bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
ubiquitin bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
protein-containing complex bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
protein-folding chaperone bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
FBXO family protein bindingBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
ubiquitin protein ligase activityBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
ubiquitin-protein transferase activityBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
cysteine-type endopeptidase inhibitor activityBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
protein bindingBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
enzyme bindingBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
metal ion bindingBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
ubiquitin protein ligase activityBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
cytoplasmE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleusE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleoplasmE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cytoplasmE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
cytosolE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleusE3 ubiquitin-protein ligase XIAPHomo sapiens (human)
nucleusBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
nucleoplasmBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
cytoplasmBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
cytosolBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
protein-containing complexBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
nucleusBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
cytoplasmBaculoviral IAP repeat-containing protein 3Homo sapiens (human)
XY bodyBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
nucleusBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cytoplasmBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cytosolBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cytoplasmic side of plasma membraneBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
CD40 receptor complexBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
nucleusBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
cytoplasmBaculoviral IAP repeat-containing protein 2Homo sapiens (human)
nucleusBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
nucleoplasmBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
cytoplasmBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
Golgi apparatusBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
centrosomeBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
cytosolBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
cytoplasmBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
nucleusBaculoviral IAP repeat-containing protein 7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1659177Allosteric inhibition of Flavivirus NS2B-NS3 protease2020Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
Inhibitors of the Zika virus protease NS2B-NS3.
AID1196850Inhibition of N-terminal His-Tb-tagged XIAP BIR2-3 (124 to 356) (unknown origin) assessed as activation of caspase-3 measured every 3 mins for 90 mins by fluorescence assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.
AID1659178Inhibition of Zika virus NS2B-NS3 protease by cell based assay2020Bioorganic & medicinal chemistry letters, 03-01, Volume: 30, Issue:5
Inhibitors of the Zika virus protease NS2B-NS3.
AID1553574Binding affinity to cIAP1-BIR3 domain (unknown origin)2019Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12
Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives.
AID1196849Binding affinity to human N-terminal His-tagged XIAP BIR2-3 C202A/C213G mutant after 60 mins by HTRF assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.
AID1553575Binding affinity to cIAP2-BIR3 domain (unknown origin)2019Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12
Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives.
AID1196858Toxicity in Balb/C athymic (nu+/nu+) mouse xenografted with human A875 cells assessed as change in body weight at 1 mg/kg, iv administered every 3 days for 6 doses relative to vehicle-treated control2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.
AID1196852Cytotoxicity against cIAP/XIAP-dependent human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.
AID1196853Cytotoxicity against XIAP-dependent human A875 cells assessed as cell viability after 72 hrs by MTS assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.
AID1196855Antitumor activity against human A875 cells xenografted in Balb/C athymic (nu+/nu+) mouse assessed as tumor growth inhibition at 1 mg/kg, iv administered every 3 days for 6 doses relative to vehicle-treated control2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.
AID1196856Antitumor activity against human A875 cells xenografted in Balb/C athymic (nu+/nu+) mouse assessed as tumor cure rate at 1 mg/kg, iv administered every 3 days for 6 doses2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.
AID1196848Binding affinity to human N-terminal His-tagged cIAP1 BIR2-3 C202A/C213G mutant after 60 mins by HTRF assay2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.
AID1300241Drug metabolism of the compound assessed as N-{1S-[2R-(6,6'-Difluoro-2'-{4S-hydroxy-1-[2-(2-methylamino-propionylamino)-butyryl]-pyrrolidin-2R-ylmethyl}-3'-oxo-2'R,3'-dihydro-1H,1'H-[2,2']biindolyl-3-ylmethyl) 4Shydroxy-pyrrolidine-1-carbonyl]-propyl}-2S-2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Electrophilic Oxidation and [1,2]-Rearrangement of the Biindole Core of Birinapant.
AID1300242Drug metabolism of the compound assessed as N-{1S-[2R-(6,6'-Difluoro-2'-{4S-hydroxy-1-[2-(2-methylamino-propionylamino)-butyryl]-pyrrolidin-2R-ylmethyl}-3'-oxo-2'S,3'-dihydro-1H,1'H-[2,2']biindolyl-3-ylmethyl)-4S-hydroxypyrrolidine-1-carbonyl]-propyl}-2S-2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Electrophilic Oxidation and [1,2]-Rearrangement of the Biindole Core of Birinapant.
AID1553576Binding affinity to ML-IAP-BIR domain (unknown origin)2019Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12
Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives.
AID1300238Drug degradation of the compound at 40 degC/75% RH measured after 1 year by HPLC analysis2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Electrophilic Oxidation and [1,2]-Rearrangement of the Biindole Core of Birinapant.
AID1300239Drug metabolism of the compound assessed as N-{1S-[2R-(6,6'-Difluoro-3S-hydroxy-3'-{4S-hydroxy-1-[2S-(2S-methylaminopropionylamino)-butyryl]-pyrrolidin-2R-ylmethyl}-3H,1'H-[2,2']biindolyl-3-ylmethyl)-4Shydroxy-pyrrolidine1 carbonyl]-propyl}-2S-methylamino2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Electrophilic Oxidation and [1,2]-Rearrangement of the Biindole Core of Birinapant.
AID1553565Binding affinity to XIAP-BIR3 domain (unknown origin)2019Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12
Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives.
AID1196857Toxicity in Balb/C athymic (nu+/nu+) mouse xenografted with human A875 cells assessed as overt signs of toxicity at 1 mg/kg, iv administered every 3 days for 6 doses2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity.
AID1300240Drug metabolism of the compound assessed as N-{1S-[2R-(6,6'-Difluoro-3R-hydroxy-3'-{4S-hydroxy-1-[2S-(2S-methylaminopropionylamino)-butyryl]-pyrrolidin-2R-ylmethyl}-3H,1'H-[2,2']biindolyl-3-ylmethyl)-4Shydroxy-pyrrolidine-1-carbonyl]-propyl}2S-methylamino2016ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3
Electrophilic Oxidation and [1,2]-Rearrangement of the Biindole Core of Birinapant.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1346157Human X-linked inhibitor of apoptosis (Inhibitors of apoptosis (IAP) protein family)2013Breast cancer research and treatment, Jan, Volume: 137, Issue:2
Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
AID1346249Human baculoviral IAP repeat containing 2 (Inhibitors of apoptosis (IAP) protein family)2013Breast cancer research and treatment, Jan, Volume: 137, Issue:2
Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (74)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's46 (62.16)24.3611
2020's28 (37.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.35 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index55.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.70%)5.53%
Reviews3 (4.05%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other69 (93.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]